Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Open Label, Phase 1b/2 Study to Study the Efficacy and Safety of MIL62 Plus Lenalidomide in Subjects With Relapsed/Refractory Follicular Lymphoma or Marginal Zone Lymphoma

NCT04110301 is registered in ClinicalTrials.gov with Beijing Mabworks Biotech Co., Ltd. as lead sponsor.

NCT NCT04110301
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04110301 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Open Label, Phase 1b/2 Study to Study the Efficacy and Safety of MIL62 Plus Lenalidomide in Subjects With Relapsed/Refractory Follicular Lymphoma or Marginal Zone Lymphoma
Lead sponsor
Beijing Mabworks Biotech Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 28, 2019
Completion date
May 31, 2025
Enrollment
53 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma and marginal zone lymphoma